EA200600356A1 - Комбинированная терапия для гликемического контроля - Google Patents

Комбинированная терапия для гликемического контроля

Info

Publication number
EA200600356A1
EA200600356A1 EA200600356A EA200600356A EA200600356A1 EA 200600356 A1 EA200600356 A1 EA 200600356A1 EA 200600356 A EA200600356 A EA 200600356A EA 200600356 A EA200600356 A EA 200600356A EA 200600356 A1 EA200600356 A1 EA 200600356A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glycemic control
combined therapy
diabetes mellitus
diabetes
niddm
Prior art date
Application number
EA200600356A
Other languages
English (en)
Russian (ru)
Inventor
Ханс-Ульрих Демут
Конрад Глунд
Маттиас Хоффманн
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA200600356A1 publication Critical patent/EA200600356A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EA200600356A 2003-09-02 2004-09-02 Комбинированная терапия для гликемического контроля EA200600356A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49953503P 2003-09-02 2003-09-02
PCT/IB2004/003082 WO2005020983A2 (en) 2003-09-02 2004-09-02 Combination therapy for glycaemic control

Publications (1)

Publication Number Publication Date
EA200600356A1 true EA200600356A1 (ru) 2006-08-25

Family

ID=34272835

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600356A EA200600356A1 (ru) 2003-09-02 2004-09-02 Комбинированная терапия для гликемического контроля

Country Status (14)

Country Link
US (1) US20060287251A1 (OSRAM)
EP (1) EP1663200A2 (OSRAM)
JP (1) JP2007504213A (OSRAM)
KR (1) KR20060119927A (OSRAM)
CN (1) CN1845731A (OSRAM)
AU (1) AU2004267955A1 (OSRAM)
BR (1) BRPI0413204A (OSRAM)
CA (1) CA2536432A1 (OSRAM)
EA (1) EA200600356A1 (OSRAM)
IL (1) IL173844A0 (OSRAM)
MX (1) MXPA06002127A (OSRAM)
NO (1) NO20061085L (OSRAM)
WO (1) WO2005020983A2 (OSRAM)
ZA (1) ZA200601770B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526291D0 (en) * 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
GB0623892D0 (en) * 2006-11-29 2007-01-10 Medical Res Council Technology Assay
JP2013523620A (ja) * 2010-03-26 2013-06-17 ノヴォ ノルディスク アー/エス 新規のグルカゴンアナログ
SG11201401175SA (en) * 2011-10-28 2014-09-26 Sanofi Aventis Deutschland Treatment protocol of diabetes type 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE29924609U1 (de) * 1999-05-28 2004-04-22 Probiodrug Ag Neue Effektoren von Dipeptidylpeptidase IV
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
IL163629A0 (en) * 2002-02-28 2005-12-18 Prosidion Ltd Glutaminyl derivatives and pharmaceutical compositions containing the same
AU2003293311A1 (en) * 2002-09-18 2004-04-23 Prosidion Ltd. Secondary binding site of dipeptidyl peptidase iv (dp iv)

Also Published As

Publication number Publication date
WO2005020983A3 (en) 2005-07-28
IL173844A0 (en) 2006-07-05
KR20060119927A (ko) 2006-11-24
CN1845731A (zh) 2006-10-11
ZA200601770B (en) 2007-07-25
CA2536432A1 (en) 2005-03-10
WO2005020983A2 (en) 2005-03-10
NO20061085L (no) 2006-05-31
JP2007504213A (ja) 2007-03-01
US20060287251A1 (en) 2006-12-21
MXPA06002127A (es) 2006-05-31
EP1663200A2 (en) 2006-06-07
BRPI0413204A (pt) 2006-10-03
AU2004267955A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
TW200502385A (en) Modulation of forkhead box o1a expression
EA200600235A1 (ru) Трёхзамещённые производные арилов и гетероарилов в качестве модуляторов метаболизма и профилактика и лечение связанных с ними нарушений
DE602004022982D1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
IL198922A0 (en) Chemical compounds and uses
WO2008016648A3 (en) Certain chemical entities, compositions and methods
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
NO20072136L (no) Substans som fremmer GH-sekresjon og anvendelse derav
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
IL186356A0 (en) Method of treating of preventing type-2 diabetes
EA200600778A1 (ru) 1,3-диметилбутилкарбоксанилиды для борьбы с нежелательными микроорганизмами
EA200600356A1 (ru) Комбинированная терапия для гликемического контроля
WO2003101284A3 (en) Methods of diagnosing and treating diabetes and insulin resistance
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
DE602004018162D1 (de) hERG1-KANAL-ÖFFNER ZUR BEHANDLUNG VON HERZARRYTHMIEN
WO2003103606A3 (en) Methods and compositions for treating and diagnosing diabetes
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
WO2024229151A3 (en) Multimeric coronavirus binding molecules and uses thereof
EP2096120A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
WO2003102161A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
BRPI0506793A (pt) métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
EP1465911A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES, INSULIN RESISTANCE AND DYSLIPIDEMIA
ATE328602T1 (de) Kombinationspräparat zur behandlung des diabetes mellitus